MedTrace Logo

Nutrition, Immunity, and Covid-19 in Obese People

NCT04979065 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2024-06-04

No results posted yet for this study

Summary

The increased risk of transmission of COVID-19 infection causes the incidence of death in health workers to escalate. It requires further research on risk factors and intervention in health worker professionals, especially on immunity factors and nutritional status. Quality of diet and nutrition is very important to support the immune system when infected. Several probiotic strains have been shown to decrease the duration and incidence of diarrhea and respiratory infections, suggesting the Gut-Lung Axis pathway. Some probiotics also improve the balance of diversity in the composition of the gut microbiota and affect body weight in obese people. Probiotics have also been shown to improve vitamin D absorption. A combination of vitamin D and probiotics may be an alternative to reduce gut dysbiosis that will directly or indirectly reduce the risk and severity of viral infections including SARS-CoV-2.

Conditions

  • Vitamin D Deficiency
  • Covid19
  • Overweight and Obesity
  • Immune Deficiency

Interventions

DIETARY_SUPPLEMENT

Probiotics, Vitamin D

Combination of two supplement that given separately

OTHER

Placebo

Placebo with inactive ingredient

Sponsors & Collaborators

  • Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia

    collaborator OTHER_GOV

  • Indonesia University

    lead OTHER

Principal Investigators

  • Rina Agustina, MD, PhD · HNRC-IMERI, Faculty of Medicine Universitas Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-24
Primary Completion
2022-04-30
Completion
2022-12-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04979065 on ClinicalTrials.gov